Why does clinical trial transparency matter?
Patients, their families, friends, physicians, colleagues, and communities are at the heart of the AllTrials campaign, which calls for all clinical trials (medical studies in which potential drug treatments are tested on people) to be registered, and their results reported.
Some people have come to support the campaign because they are battling or have battled a disease; others sign on after working to help loved ones.
These are their stories.
Peer-to-peer stories from researchers and physicians are in BLUE folders.
Stories from patients and patient advocates are in RED folders.
Have a clinical trial story to tell?
*Please note that while this is a forum for patients to have their say, we strive for factual accuracy in our interview reporting.
Comments in response to the stories do not represent the ideas or views of the organization.
“The need for research transparency … is really ensuring that everyone has access to the best drug treatment possible with the most information about the risk and safety of those drugs,” says Josh Morrison, a living kidney donor and the co-founder of the living donation advocacy nonprofit, Waitlist Zero.
“I think transparency on all levels is crucial,” says Gina Szajnuk, a mother of three who co-founded the Rare and Undiagnosed Network (RUN) after she and her children began suffering from an undiagnosed condition.
A conversation with Paula Kozik of the National Ovarian Cancer Coalition. After being diagnosed with ovarian cancer, Kozik took a leap of faith and enrolled in a clinical trial to combat her disease.
AllTrials is an initiative of Ben Goldacre, BMJ, Centre for Evidence-based Medicine, Cochrane Collaboration, James Lind Initiative, PLOS and Sense About Science, and is being led in the U.S. by Sense About Science USA, Dartmouth’s Geisel School of Medicine and the Dartmouth Institute for Health Policy & Clinical Practice.